{
    "organizations": [],
    "uuid": "4b1f22b8a19918bae779b574eabad7b1024d966a",
    "author": "",
    "url": "https://www.reuters.com/article/brief-lilly-reports-additional-top-line/brief-lilly-reports-additional-top-line-results-from-cyramza-phase-3-range-study-idUSFWN1RX0UJ",
    "ord_in_thread": 0,
    "title": "BRIEF-Lilly Reports Additional Top-Line Results From Cyramza Phase 3 Range Study",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 20, 2018 / 6:58 PM / in an hour BRIEF-Lilly Reports Additional Top-Line Results From Cyramza Phase 3 Range Study Reuters Staff 1 Min Read \nApril 20 (Reuters) - Eli Lilly and Co: \n* LILLY REPORTS ADDITIONAL TOP-LINE RESULTS FROM CYRAMZAÂ® (RAMUCIRUMAB) PHASE 3 RANGE STUDY IN ADVANCED OR METASTATIC UROTHELIAL CANCER \n* SAYS SIGNIFICANT IMPROVEMENT IN PRIMARY ENDPOINT OF PROGRESSION-FREE SURVIVAL PREVIOUSLY REPORTED * SAYS IMPROVEMENT IN OBJECTIVE RESPONSE RATE OBSERVED \n* SAYS POSITIVE TREND IN OVERALL SURVIVAL DID NOT REACH STATISTICAL SIGNIFICANCE * SAYS NO NEW SAFETY SIGNALS WERE OBSERVED \n* SAYS POSITIVE TREND WAS SEEN IN SECONDARY ENDPOINT OF OVERALL SURVIVAL WHICH DID NOT REACH STATISTICAL SIGNIFICANCE \n* SAYS SAFETY PROFILE OBSERVED IN RANGE STUDY CONSISTENT WITH WHAT WAS SEEN PREVIOUSLY IN TRIAL & HAS BEEN PREVIOUSLY OBSERVED FOR CYRAMZA Source text for Eikon: Further company coverage:",
    "published": "2018-04-20T21:57:00.000+03:00",
    "crawled": "2018-04-20T22:50:43.004+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "pm",
        "hour",
        "report",
        "additional",
        "result",
        "cyramza",
        "phase",
        "range",
        "study",
        "reuters",
        "staff",
        "min",
        "read",
        "april",
        "reuters",
        "eli",
        "lilly",
        "co",
        "lilly",
        "report",
        "additional",
        "result",
        "ramucirumab",
        "phase",
        "range",
        "study",
        "advanced",
        "metastatic",
        "urothelial",
        "cancer",
        "say",
        "significant",
        "improvement",
        "primary",
        "endpoint",
        "survival",
        "previously",
        "reported",
        "say",
        "improvement",
        "objective",
        "response",
        "rate",
        "observed",
        "say",
        "positive",
        "trend",
        "overall",
        "survival",
        "reach",
        "statistical",
        "significance",
        "say",
        "new",
        "safety",
        "signal",
        "observed",
        "say",
        "positive",
        "trend",
        "seen",
        "secondary",
        "endpoint",
        "overall",
        "survival",
        "reach",
        "statistical",
        "significance",
        "say",
        "safety",
        "profile",
        "observed",
        "range",
        "study",
        "consistent",
        "seen",
        "previously",
        "trial",
        "previously",
        "observed",
        "cyramza",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}